Gencove develops a low-pass genome sequencing platform coupled with analytics SaaS, operating a laboratory in New York. The company offers low-pass sequencing and interpretation tools and has built large cross-species genomic datasets and reference panels. Its customers include academic, agriculture, biotechnology, and pharmaceutical organizations. Gencove says it is democratizing genome sequencing by making genomic information more accessible and interpretable. The company plans to use new funding for further product development, commercial growth, and to build out key business functions. As of the reported round, Gencove has raised a total of $16.2 million. Gencove is a NYC-based low-pass genome sequencing platform led by CEO Joe Pickrell and founded by scientists from the New York Genome Center. It develops technologies that enable high-throughput, low-cost genome sequencing and uses genome imputation to produce high-quality genomic interpretation from small amounts of sequencing data. The company works with technology partners including BGI and SeqWell. Customers span consumer, clinical, and agricultural markets and include the Broad Institute, the University of Michigan, and Oxford University. Gencove raised $3M in funding to expand commercial operations in human genetics and to develop new applications for agricultural markets. As part of the financing, Spero partner Shripriya Mahesh will join Gencove’s board of directors.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2021